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Abstract
Background: While survival of systemic lupus erythematosus (SLE) patients has improved substantially, problems
remain in the management of their emotional health. Medium to high-dose glucocorticoid doses are known to
worsen emotional health; the effect is unclear among patients receiving relatively low-dose glucocorticoids. This
study aims to investigate the association between low glucocorticoid doses and emotional health in lupus low
disease activity state (LLDAS).
Methods: This cross-sectional study drew on data from SLE patients in 10 Japanese institutions. The participants
were adult patients with SLE duration of ≥ 1 year who met LLDAS criteria at the study visit from April 2018 through
September 2019. The exposure was the daily glucocorticoid dose (mg oral prednisolone). The outcome was the
emotional health score of the lupus patient-reported outcome scale (range: 0 to 100). Multiple linear regression
analysis was performed with adjustment for confounders including disease-related damage, activity, and
psychotropic drug use.
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Results: Of 192 patients enrolled, 175 were included in the analysis. Their characteristics were as follows: female,
89.7%; median age, 47 years (interquartile range (IQR): 37.0, 61.0). Median glucocorticoid dose was 4.0 mg (IQR 2.0,
5.0), and median emotional health score 79.2 (IQR 58.3, 91.7). Multiple linear regression analysis showed daily
glucocorticoid doses to be associated with worse emotional health (β coefficient = − 2.54 [95% confidence interval
− 4.48 to − 0.60], P = 0.01).
Conclusions: Daily glucocorticoid doses were inversely associated with emotional health among SLE patients in
LLDAS. Further studies are needed to determine whether glucocorticoid tapering leads to clinically significant
improvements in emotional health.
Keywords: Systemic lupus erythematosus, Glucocorticoid, Emotional health, Patient-reported outcome, Depression,
Anxiety, Cross-sectional study
Background
Systemic lupus erythematosus (SLE) is a chronic, pro-
gressive autoimmune disease that frequently affects
young women and can cause damage to organs such as
the kidney, heart, lungs, and central nervous system. In
SLE patients with high disease activity, irreversible organ
damage is likely to occur and the 10-year survival was
50% to 60% until the early 1960s [1]. However, with the
development of therapeutic agents and better treatment
strategies, survival rates and renal survival estimates
10 years after onset have reached approximately 90% [2].
Yet while survival has improved substantially, prolonged
disease duration has a significant impact on patients’
health-related quality of life [3, 4].
One explanation of low quality of life in SLE patients
is the high prevalence of anxiety or depressive symptoms
[5], which is as high as 40% [6] compared with 4–19% in
the general population [7]. In patients with SLE, disease
activity contributes to the occurrence of depression and
anxiety [8, 9]. In addition, the use of glucocorticoids,
which are important therapeutic agents even now, has
been known to worsen mental health due to weight gain
and cosmetic side effects [10]. Neuropsychiatric symp-
toms due to the use of glucocorticoids are widely known,
whereas no significant association between such impair-
ments of emotional health and glucocorticoid doses has
been found in previous studies on quality of life in SLE
patients [3, 11]. One study suggested that disease activity
could be a potential effect-modifier of the association
between emotional health and glucocorticoid doses [11].
To date, there are no reports on the association of emo-
tional health with the limited doses of glucocorticoids
used for SLE patients with low disease activity.
In recent years, criteria for lupus low disease activity
state (LLDAS) as a therapeutic target for SLE patients
have been proposed [12]. The achievement of LLDAS on
yearly assessments was negatively associated with the
risk of damage accrual [13], compared with those with
unstable disease activity, whose control of disease activ-
ity should be prioritized. In the present study, therefore,
we aimed to evaluate emotional health in SLE patients
in the low disease activity state and to assess the associ-
ation between emotional health and the prescribed daily
dose of oral glucocorticoid.
Methods
Study design and setting
This was a cross-sectional study using data captured by
an ongoing multidisciplinary cohort study (the Lupus
registry of Nationwide institutions (LUNA)), which was
established in 2016 to investigate the association be-
tween clinical manifestations, socioeconomic back-
ground, and outcomes in SLE patients reported from 10
Japanese institutions. LUNA contains data on patients
aged 20 years or older diagnosed according to the re-
vised 1997 American College of Rheumatology (ACR)
criteria [14] for classification of SLE; in LUNA approxi-
mately 900 cases, 1.5% of SLE patients in Japan have
been registered.
Data collection
This study was performed using information derived
from self-administered questionnaires completed by reg-
istered patients or from electronic medical records from
April 2018 through September 2019. Data collection was
performed annually for each patient and if more than
one survey was conducted during the study, only the
earliest recorded data were used.
Study population
Patients registered in LUNA were eligible for this study
if all three of the following criteria were met: (1) at least
1 year since SLE onset, (2) history of oral glucocorticoid
use, and (3) meeting the definition of LLDAS [12].
LLDAS attainment requires that all four of the following
criteria be met: (1) SLE Disease Activity Index 2000
(SLEDAI-2 K [15], scale 0–105) ≤ 4; (2) no active symp-
toms of major organ involvement (renal, central nervous
system, cardiopulmonary, vasculitis, or fever), and no
hemolytic anemia or gastrointestinal activity; (3)
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physician global assessment (PGA, scale 0–3) ≤ 1; and
(4) current prednisolone (or equivalent) dose ≤ 7.5 mg
daily and well-tolerated standard maintenance doses of
immunosuppressive drugs.
Exposure
The exposure was the prescribed daily amount of oral
glucocorticoid used at the time of the survey (mg of oral
prednisolone per day or its equivalent). If the patient’s
prescribed glucocorticoid dose was unknown, it was
handled as missing.
Outcome measures
The outcome measure was the emotional health domain
score out of 12 domains in the Japanese version of lupus
patient-reported outcome (LupusPRO) [16, 17]. The
emotional health domain consists of these six items:
worries about lupus’s impact on future, worries about
losing income, anxiety, depression, concern that lupus
(or its treatment) may lead to more health problems,
and concern that lupus-related health problems will last
a long time; each item has a five-point scale with “none
of the time,” “a little of the time,” “some of the time,”
“most of the time,” “all of the time,” and “not applicable”
(recorded as 0 for scoring) [17] used to assess anxiety
and depression caused by SLE. The emotional health do-
main of Japanese LupusPRO was verified for reliability
(Cronbach’s alpha coefficient 0.88, test-retest reliability
0.75), convergent validity (Spearman’s correlation coeffi-
cient 0.42) using Short Form-12 (SF-12) Mental Health,
and for construct validity using confirmatory factor ana-
lysis. The emotional health score of the Japanese version
of LupusPRO ranges from 0 to 100; a higher score indi-
cates less frequent presence of symptoms [16].
Potential confounders
Potential confounders based on findings from previous
studies [5, 18, 19] and from the clinical perspective of
the rheumatologist were the following seven variables:
(1) age at the time of the survey, (2) sex, (3) disease dur-
ation since SLE diagnosis, (4) damage assessed using the
Systemic Lupus International Collaborating Clinics
(SLICC)/American College of Rheumatology (ACR)
Damage Index [1], (5) disease activity measured using
the SLEDAI-2 K score, (6) current use of psychotropics
(hypnotics, mood stabilizers, anxiolytics, antidepressants,
antipsychotics), and (7) presence of hydroxychloroquine
and 8) the number of immunosuppressants.
Statistical analyses
The descriptive statistics were expressed as the median
and interquartile range for continuous variables and as n
(%) for categorical variables on patients who were
divided into four groups by 2.5 mg increments in gluco-
corticoid dose.
Complete case analysis was performed, excluding pa-
tients with missing variables in exposure, outcome, or
potential confounders. In the primary analysis, we used
a simple regression model to estimate a regression coef-
ficient with a 95% confidence interval (95% CI) between
exposures as independent variables and outcome vari-
able. Subsequently, we also conducted a multiple linear
regression (ordinary least squares regression) with
complete cases to assess the associations between the
exposure and the outcome variable after adjusting for
potential confounders. The minimal important differ-
ence (MID) in health-related quality of life measures is
generally interpreted using half a standard deviation
(SD) [20] when an anchor-based approach is unavailable,
and we used, therefore, 0.5 SD of the emotional health
score in the primary analysis population to interpret the
magnitude of emotional health impact per 1 mg of
glucocorticoid. We visually evaluated using a residual
quantile-quantile (Q-Q) plot, a histogram of residuals
for detecting violation of the normality assumption, and
a residual vs. fitted values plot for detecting non-
linearity and unequal error variances.
In the sensitivity analysis, we used multiple imputation
to handle the uncertainty caused by missing values of
potential confounders on the assumption of missing at
random. All variables in the primary analysis were used
to create 20 complete data sets in the imputation
process. The complete data sets were analyzed by the
same procedures for the primary analysis before combin-
ing the results from these analyses using Rubin’s rules.
Statistical significance level and software
All statistical testing was 2-sided; a p value of < 0.05 was
considered statistically significant. Statistical analyses in
this study were performed using the Statistical Package




Of the 850 patients surveyed between April 1, 2018, and
August 31, 2019, a total of 192 patients met the inclu-
sion criteria. The eligibility of 128 individuals could not
be determined due to missing values, and almost all in-
eligible patients (528/530 [99.6%]) were ineligible due to
failure to achieve LLDAS. We also excluded from the
primary analysis the patients with missing values of out-
come or with potential confounders. Figure 1 shows the
flow of the screening process, and Table 1 shows the pa-
tients’ baseline characteristics in the primary analysis.
The median age was 47.0 (interquartile range (IQR)
37.0, 61.0) years and 157 (89.7%) were female. Nearly
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half of this cohort was between 20 and 45 years old. The
median time since the diagnosis of SLE was 12.0 (IQR
6.0, 19.0) years, the median Systemic Lupus Inter-
national Collaborating Clinics (SLICC)/American Col-
lege of Rheumatology (ACR) Damage Index (SDI) was 0
(IQR 0.0, 1.0), and 106 (60.6%) patients had an SDI of 0.
The median SLEDAI-2 K was 2.0 (IQR 0.0, 4.0), and 55
(31.4%) patients had a SLEDAI-2 K of 0. The median
glucocorticoid dose (exposure) was 4.5 (IQR 2.0, 5.0) mg
daily. Both the characteristics of disease activity and the
dose of glucocorticoid reflected clinical quiescence in
this study population. Patients were taking SLE-related
medications, including glucocorticoid, 146 patients
(83.4%); hydroxychloroquine, 46 (26.3%); cyclophospha-
mide, 0 (0%); mycophenolate mofetil, 15 (8.6%); mizori-
bine, 12 (6.9%); methotrexate, 3 (1.7%); azathioprine, 15
(8.6%); tacrolimus, 53 (30.3%); cyclosporin, 10 (5.7%);
and belimumab, 1 (0.6%). The lower the glucocorticoid
dose, the less hydroxychloroquine was used.
Emotional health
Figure 2 shows the distribution of emotional health
scores of LupusPRO for each dose of glucocorticoid.
The median emotional health score in the primary ana-
lysis population was 79.2 (IQR 58.3, 91.7), with an aver-
age of 71.5 (SD 27.3).
Primary analysis
The results of simple regression analysis (crude) and
multiple regression analysis (adjusted) are shown in
Table 2. In the adjusted model, the partial regression
coefficient β = − 2.54 (95% CI − 4.48 to − 0.60, P = 0.01)
indicated a significant association between the
glucocorticoid dose and poorer emotional health. The
difference in emotional health score (converted using
the SD) per 1 mg of the glucocorticoid dose was − 0.09
SD (− 0.16 SD to − 0.02 SD). Residual diagnostics visu-
ally confirmed standard regression assumptions.
Sensitivity analysis
After multiple imputation of missing values, the partial
regression coefficient β = − 2.73 (95% CI − 4.63 to − 0.84,
P < 0.01) indicated a negative association between the
glucocorticoid dose and emotional health, similar to the
findings of the primary analysis.
Discussion
Using data from LUNA, a multicenter prospective Japanese
cohort, the present study brought to light the distribution
of emotional health in patients who met the criteria for
lupus low disease activity state (LLDAS). On the emotional
health domain of the LupusPRO scale, we found a negative
association with the dose of glucocorticoid, which
Fig. 1 Flow diagram of screening process in the present study. LLDAS, lupus low disease activity state
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suggested that the lower the glucocorticoid dose, the better
a patient’s emotional health.
The results of this study showed that even a low dose
of prednisolone-equivalent of 7.5 mg daily or lower was
associated with altered emotional health such as anxiety
or depression. Although cases of onset even at doses as
low as 7.5 mg or less have been reported [21], no studies
have focused on the association between such impair-
ments of emotional health as anxiety and depression and
low-dose prednisolone in patients with SLE. Neuro-
psychiatric symptoms due to the use of glucocorticoid
are widely known [22], and the association between
emotional health and daily doses of glucocorticoid
(prednisolone or equivalent 7.5 mg or more) has been
demonstrated in other diseases such as chronic obstruct-
ive pulmonary disease [23] and adrenal insufficiency
[24], but the association was not clear in SLE patients. A
previous study on SLE [3] might have adjusted
insufficiently such confounding factors as age, sex, dis-
ease duration, damage, current use of psychotropics, and
hydroxychloroquine compared to this study. Yet another
previous study, which evaluated the longitudinal associ-
ation between mental health scores and glucocorticoid
doses, used comprehensive measures of health outcome
rather than disease-specific status [11]; thus it may have
been unable to detect differences in SLE patient-specific
emotional health scores. LupusPRO may have been the
key to detecting more disease-specific anxiety and de-
pression caused by disease-specific factors in comparison
with using a comprehensive scale [11]. Items in emo-
tional health in LupusPRO assess not only anxiety and
depression, but also other emotional aspects such as
worries about lupus’s impact on the future, worries
about losing income, and concern that lupus (or its
treatment) may lead to more health problems. These
studies also included patients with a broader spectrum
Table 1 Baseline characteristics
All patients Glucocorticoid dose (by 2.5mg/day increments)






Variables N = 175 N = 29 N = 24 N = 92 N = 30
Glucocorticoid, median IQR, mg/day 4.0 [2.0–5.0] 0.0 [0.0–0.0] 1.8 [1.0–2.0] 5.0 [4.0–5.0] 6.0 [6.0–7.0]
Age, median IQR, years 47.0 [37.0–61.0] 44.0 [35.0–61.0] 49.0 [38.0–64.5] 47.5 [36.0–59.0] 47.0 [39.0–58.0]
Sex, female, n (%) 157 (89.7) 24 (82.8) 22 (91.7) 83 (90.2) 28 (93.3)
Damage index (SDI), median IQR, point 0.0 [0.0–1.0] 0.0 [0.0–0.0] 0.0 [0.0–1.0] 0.0 [0.0–1.0] 0.5 [0.0–1.0]
Time since SLE diagnosis, median IQR, year 12.0 [6.0–19.0] 10.0 [5.0–16.0] 11.0 [6.5–19.0] 12.0 [7.0–20.0] 15.0 [7.0–22.0]
Disease activity index (SLEDAI-2 K),
median IQR, point
2.0 [0.0–4.0] 2.0 [1.0–4.0] 2.0 [0.5–4.0] 2.0 [0.0–4.0] 2.0 [0.0–2.0]
Hydroxychloroquine, n (%) 46 (26.3) 3 (10.3) 5 (20.8) 24 (26.1) 14 (46.7)
Number of Immunosuppressants
1, n (%) 78 (44.6) 7 (24.1) 6 (25.0) 50 (54.3) 15 (50.0)
2, n (%) 15 (8.6) 3 (10.3) 2 (8.3) 5 (5.4) 5 (16.7)
Immunosuppressants
Cyclophosphamide, n (%) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Mycophenolate mofetil, n (%) 15 (8.6) 2 (6.9) 2 (8.3) 7 (7.6) 4 (13.3)
Mizoribine, n (%) 12 (6.9) 1 (3.4) 3 (12.5) 6 (6.5) 2 (6.7)
Methotrexate, n (%) 3 (1.7) 1 (3.4) 0 (0.0) 1 (1.1) 1 (3.3)
Azathioprine, n (%) 15 (8.6) 0 (0.0) 1 (4.2) 11 (12.0) 3 (10.0)
Tacrolimus, n (%) 53 (30.3) 8 (27.6) 3 (12.5) 28 (30.4) 14 (46.7)
Cyclosporine, n (%) 10 (5.7) 1 (3.4) 1 (4.2) 7 (7.6) 1 (3.3)
Antipsychotics, n (%) 10 (5.7) 0 (0.0) 2 (8.3) 5 (5.4) 3 (10.0)
History of diagnosis
Neuropsychiatric lupus, n (%) 6 (3.4) 2 (6.9) 1 (4.2) 2 (2.2) 1 (3.3)
Lupus nephritis, n (%) 38 (21.7) 6 (20.7) 3 (12.5) 23 (25.0) 6 (20.0)
Note: Values are presented as the median and numbers in brackets indicate interquartile ranges for continuous variables. Categorical variables are presented as
the number and (in parentheses) the percentage of patients divided into four groups by 2.5 mg increments in glucocorticoid dose
IQR interquartile range, SDI Systemic Lupus International Collaborating Clinics (SLICC)/American College of Rheumatology (ACR) Damage Index, SLEDAI-2 K
Systemic Lupus Erythematosus Disease Activity Index 2000
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of disease activity, which could be an important effect
modifier, and these may help to explain the findings of
the present study.
This study has several limitations. First, we were un-
able to select variables for socioeconomic status as co-
variates because of the high proportion of missing values
of such variables as marital status and educational at-
tainment. A previous analysis of the quality of life of
SLE patients reported that the influence of these socio-
economic status variables is not associated with quality
of life [25]. The residual confounding effects of such un-
measured variables as history of mental disorder, re-
lapses of disease activity occurring within the past year,
duration of LLDAS, past treatment experience, and cu-
mulative doses of glucocorticoid from the onset have
not been taken into account. Past disease activity and
Fig. 2 Distribution of emotional health scores according to the dose of glucocorticoid. We used a box-and-whiskers plot to describe the scores
on the emotional health domain of Japanese LupusPRO ranging from 0 to 100 (vertical axis) in each dose category of glucocorticoid. LupusPRO,
lupus patient-reported outcome
Table 2 Primary analysis: association between the glucocorticoid dose and emotional health (complete case analysis)
Crude Adjusted
Variables β coefficient [95%CI] P value β coefficient [95%CI] P value
Glucocorticoid, mg/day (per additional mg/day) − 2.12 [− 3.99, − 0.26] 0.03 − 2.54 [− 4.48, − 0.60] 0.01
Age, years (per 1 year older) − 0.20 [− 0.55, 0.16] 0.28
Sex, female (vs. male) 11.81 [− 2.10, 25.72] 0.10
Damage index (SDI), point (per additional point) − 0.90 [− 4.36, 2.55] 0.61
Time since diagnosis of SLE, year (per additional year) 0.30 [− 0.15, 0.75] 0.19
Disease activity index (SLEDAI-2 K), point (per additional point) − 0.77 [− 3.37, 1.83] 0.56
Hydroxychloroquine (vs. absent) 0.56 [−8.96, 10.07] 0.91
Antipsychotics (vs. absent) − 1.29 [− 18.88, 16.30] 0.89
Number of immunosuppressants (per additional count) 5.00 [− 1.42, 11.42] 0.13
Note: Covariates: Crude: unadjusted. Adjusted: adjusted for age at the time of the survey, sex, time since diagnosis of SLE, damage index, disease activity index,
current use of psychotropics (hypnotics, mood stabilizers, anxiolytics, antidepressants, antipsychotics) and the presence of the
immunomodulator hydroxychloroquine
SDI Systemic Lupus International Collaborating Clinics (SLICC)/American College of Rheumatology (ACR) Damage Index, SLEDAI-2 K Systemic Lupus Erythematosus
Disease Activity Index 2000, SLE systemic lupus erythematosus. 95% confidence intervals (CI) in brackets
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cumulative glucocorticoid doses are associated with SDI
[26]. Both the number of concomitant immunosuppres-
sants and SDI were adjusted to minimize the impact of
residual confounding factors in this study, but this at-
tempt may have been insufficient. Second, most patients
in this study were followed in a tertiary care practice,
and therefore, these results may not be applicable to pa-
tients with LLDAS in other settings. Patients who gener-
ally go to a secondary or tertiary care institution have a
clinically severe course; thus, we should consider that
the population in this study actually tends to have
poorer emotional health scores than SLE patients with
LLDAS as a whole. Third, the cross-sectional nature of
this study may cause reverse causality, which may have
resulted in attribution of lower doses of glucocorticoids
to patients with good emotional health.
This study’s strengths are first that it was conducted
using clinical data collected from a prospective multi-
center cohort study as an objective measure of the fea-
tures and outcomes of SLE patients. Second, in order to
scrutinize the association between emotional health and
the glucocorticoid dose, considering effect modification
by disease activity, we separated SLE patients into sub-
groups using the criteria for LLDAS proposed in 2016.
Third, our study had more statistical power with a
greater sample size than that of previous studies on
quality of life of SLE patients, which had sample sizes of
about 100 participants.
The aggressive use of hydroxychloroquine and other
immunosuppressive drugs during the periods of
remission-maintenance might make further reductions
in glucocorticoid doses possible, thereby permitting im-
provements in emotional health that exceed the minimal
important difference. Recent clinical practice guidelines
state that the glucocorticoid dose can be tapered as long
as the disease activity is stable; however, a lack of con-
sensus exists regarding the tapering schedules and main-
tenance dose of glucocorticoid [27]. Although no data
on minimal important differences [28] in emotional
health of LupusPRO have been reported and this cross-
sectional study is limited to mentioning minimal import-
ant differences in individuals, every 1 mg increase in the
dose of glucocorticoid is equivalent to a 0.09 SD lower
emotional health score, indicating that a 0.5 SD differ-
ence, generally considered the minimal important differ-
ence [20], corresponds to a 5–6 mg per day dose of
glucocorticoid. Further studies are needed to determine
whether reducing the glucocorticoid dose is indeed pos-
sible, whether glucocorticoid tapering is associated with
the achievement of the minimal important difference in
emotional health, and whether similar results are con-
firmed using other disease-specific measures such as
LupusQOL, for which the minimal important difference
has already been established.
Conclusion
The daily dose of glucocorticoid was negatively associ-
ated with emotional health among systemic lupus ery-
thematosus patients in lupus low disease activity state.
Further longitudinal studies are needed to determine
whether glucocorticoid tapering is associated with clinic-
ally significant improvements based on LupusPRO’s
minimal important difference in emotional health in pa-
tients in lupus low disease activity state.
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